Ulysses Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ulysses Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.37M	Hold	15,000	–	–	0.47%	26
2026 Q1	$1.92M	Hold	15,000	–	–	0.24%	25
2025 Q4	$1.83M	Buy	+15,000	New	+$1.72M	0.34%	28
2025 Q2	–	Sell	-15,000	Closed	-$1.22M	–	66
2025 Q1	$1.22M	Hold	15,000	–	–	0.18%	34
2024 Q4	$1.35M	Sell	15,000 -6,500	-30%	-$630K	0.22%	39
2024 Q3	$2.12M	Buy	21,500 +4,000	+23%	+$393K	0.2%	37
2024 Q2	$1.62M	Hold	17,500	–	–	0.23%	39
2024 Q1	$1.66M	Buy	17,500 +13,000	+289%	+$1.21M	0.14%	40
2023 Q4	$402K	Buy	+4,500	New	+$334K	0.04%	46
2023 Q3	–	Sell	-15,000	Closed	-$1.25M	–	59
2023 Q2	$1.25M	Sell	15,000 -2,500	-14%	-$209K	0.11%	38
2023 Q1	$1.33M	Buy	17,500 +600	+4%	+$49.8K	0.28%	34
2022 Q4	$1.4M	Buy	16,900 +11,900	+238%	+$963K	0.34%	25
2022 Q3	$397K	Buy	+5,000	New	+$422K	0.06%	42
2017 Q3	–	Sell	-10,000	Closed	-$771K	–	59
2017 Q2	$771K	Buy	+10,000	New	+$709K	0.1%	53

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Ulysses Management's XBI Position: Q2 2026 in Review

Ulysses Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 15,000 shares worth $2.37M. The position accounts for 0.47% of the portfolio, ranked #26.

Ulysses Management first reported a position in XBI in Q2 2017 and has held it in 14 quarters since. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Ulysses Management held 15,000 shares of State Street SPDR S&P Biotech ETF worth $2.37M as of Q2 2026.
Ulysses Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.47% of Ulysses Management's portfolio in Q2 2026, its #26 holding.
Ulysses Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and has held it in 14 quarters since.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Ulysses Management's 13F filing for Q2 2026, filed 14 Aug 2026.